The report notes a 1.5% YoY revenue decline and 24% YoY EBITDA decline in Q2FY27 due to lower lenalidomide sales, but states the company remains confident of medium-term growth from semaglutide relaunch, biosimilars and CDMO expansion, maintaining a Buy rating with FY27/FY28 estimates revised down for FY27 and mixed for FY28.
Read this note →09 Nov 2026, 16:09 IST · Shriram Financial Services Private Limited (Formerly known as Way2Wealth Brokers Pvt. Ltd.)
RR09112026ba19b
1 company covered in this note, hosted by Way2Wealth. Each view below is Shriram Financial Services Private Limited (Formerly known as Way2Wealth Brokers Pvt. Ltd.)'s, not Orivam's.